Key Takeaways for Illumina Stock as of August 2026
- Rally: Illumina stock is up 92% over the past year to $193.
- Coverage Split: Nineteen analysts cover the stock with 6 buys, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $199 mean target sits just 3% above the current price.
- Model Upside: TIKR’s mid-case valuation targets $256 by December 2030, implying 33% total return and a 7% annualized rate.
- Guidance Raise: Illumina lifted full-year revenue guidance to $4.60 billion-$4.64 billion and EPS guidance to $5.30-$5.40 after a second-quarter beat.
Illumina Stock’s 92% Rally Traces Back to a Clinical Reacceleration Wall Street Missed
Illumina (ILMN) stock has climbed 92% over the past year, rising from roughly $100 in August 2025 to $193.14 at the August 17, 2026 close. The gain wasn’t a straight line: the stock dipped into the mid-$100s last winter before a steady climb from April through July pushed it above $200 in early August.
The turn traces to a reacceleration in the clinical sequencing business that the market had priced as fading. Illumina’s second-quarter revenue of $1.16 billion, reported on July 30, rose 9.5% year over year and beat the $1.13 billion analysts expected, while non-GAAP earnings of $1.31 per share topped the $1.23 consensus. Management raised full-year revenue guidance to $4.60 billion-$4.64 billion and lifted its non-GAAP EPS outlook to $5.30-$5.40, up from $5.15-$5.30 heading into the quarter.
Clinical consumables, which make up roughly 65% of sequencing consumables revenue, now carry a mid-teens growth guide for the year, an upgrade from where management started 2026. CEO Jacob Thaysen dismissed the idea that clinical demand was running out of room when a Q2 earnings call question raised the prospect of a slowdown directly: “Talking about the clinical cliff, I agree, it’s not a cliff. It’s a wave, and we are surfing it as you are saying.” NovaSeq X placements topped 95 units for a second straight quarter, more than three years after launch, with instrument revenue up 31% to $125 million.
The re-rating shows up in the multiple too. Illumina stock traded at 35 times next-twelve-month earnings after the print, up from 23 times three months earlier, a repricing that reflects the market betting on the clinical wave rather than doubting it.
Illumina Stock Clears an Icahn Overhang as Insiders Cash Out
The rally has also coincided with the fading of a governance overhang tied to Carl Icahn’s 2023 campaign against the company. A Delaware court will hold a dismissal hearing on November 2 in the Icahn Partners-led stockholder suit tied to the GRAIL acquisition, with the case set to be dismissed with prejudice for the plaintiffs, though separate derivative claims remain pending.
Director Keith Meister, a longtime Icahn ally who joined the board during that fight, sold 739,127 shares for roughly $149 million on August 4 and 5 at prices between $197 and $203, trimming his indirect stake to about 2.09 million shares. The sale reads less like a loss of conviction than profit-taking into a stock that has nearly doubled since he joined the board.
Illumina Stock’s Price Targets Finally Catch Up to the Rally
Nineteen analysts now cover Illumina stock with a mean target of $199, just 3% above the $193 close on August 17. The current ratings split runs 6 buys, 4 outperforms, 6 holds, 3 underperforms and 1 sell.
That gap has closed the hard way. A year ago, on June 29, 2025, the $109 mean target sat 15% above a stock trading near $95. By December 28, 2025, the stock had jumped to $135 while the mean target crawled to $125, a 7% discount to the price. The pattern repeated in 2026: the mean target sat 16% above the price in March, then fell to a 14% discount by June 28 as the stock surged to $177 faster than analysts could raise targets.
Coverage has also thinned, from 23 analysts in June 2025 to 19 now, even as the stock roughly doubled. Fewer analysts covering a stock that kept outrunning their targets is consistent with a name the Street is still catching up to rather than one it has gotten ahead of.
TIKR Values Illumina Stock at $256, Pricing In a Slower Multiyear Climb
TIKR’s mid-case model values Illumina stock at $256 by December 2030, implying 33% total return from the current price of $193, or 7% annualized over 4.4 years.
That annualized rate lands well below the 92% the stock has already delivered over the past twelve months, marking Illumina stock as a name whose easiest gains may already be behind it rather than ahead.
Accordingly, the model’s implied return sits close to where the Street’s own mean target already points, and both signals agree that a stock which spent the past year chasing analyst estimates higher is now trading close to what its clinical reacceleration is worth.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
